Merrimack: Clinical Trial Update (Merrimack) - Jul 18, 2015 - “Observed safety profile of the MM-141 as a monotherapy appears comparable to expected toxicities with other IGF- 1 R and ErbB3 inhibitors”; “Recommended Phase 2 Dose of MM-141 was established for weekly dosing schedules at 20 mg/kg and for bi-weekly dosing schedules at 40 mg/kg”
P1 data • Oncology
|